The DOI matches its Crossref record; 103 of the 104 references it cites were found in a registry or an index.
Current and emerging drug treatment strategies for polycystic ovary syndrome
Abstract
INTRODUCTION: Polycystic ovary syndrome (PCOS) is a common hormonal, metabolic, and reproductive disorder with a heterogeneous phenotype. As the exact etiology of PCOS is still unclear, available pharmacotherapies are mostly directed toward alleviating symptoms and associated metabolic abnormalities. AREAS COVERED: Herein, we present an overview of the current and emerging pharmacotherapies for the management of women with PCOS who do not seek pregnancy. We performed a literature search in PubMed database up to January 2022 and reviewed papers assessing drug treatments for PCOS. We aimed to outline the most recent evidence to support treatment recommendations in these patients. EXPERT OPINION: Targets for medical treatment include hormonal, reproductive, and metabolic abnormalities in PCOS. However, none of the available pharmacological options can cover the entire spectrum of clinical manifestations observed in these patients. Considering the heterogeneity of PCOS, treatment should be individualized and adapted to specific needs of each patient. Better understanding of the molecular mechanisms underlying the pathogenesis of PCOS would help development of novel, safer, and more effective multi-targeted therapeutic strategies for the syndrome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, in clinical practice, metformin demonstrated a variety of beneficial effects on menstrual disorder, anovulation, androgen excess, insulin resistance, and cardiovascular risk, whereas its weight loss effect is often inconsistent and transient [21, 22].”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [21]
In the citing paper
“Nevertheless, there is widespread agreement that until now no pharmacological options are available to tackle the entire spectrum of clinical manifestations observed in PCOS [21].”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [21]
Citations
Cites
The mechanisms of action of metformin
Rena, G., Hardie, D. G., & Pearson, E. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4342-z · Cited by 2,287
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 1×
“GLP-1RAs also have additional effects such as slowing gastric emptying and increasing satiety, thereby reducing food intake and inducing weight loss [58,59].”
BackgroundTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.57 · Cited by 2,005 · cited 4×
“Abbreviations: ACTH, adrenocorticotropic hormone; COCs, combined oral contraceptives; FSH, follicle-stimulating hormone; GnRH, gonadotropin releasing hormone; Kiss, kisspeptin; KNDy neurons, kisspeptin-neurokinin B-dynorphin neurons; LH, luteinizing hormone; NKB, neurokinin B; SHBG, sex hormone binding globulin; SGLT2…”
BackgroundInfluentialFauser, B. C. J. M., Tarlatzis, B. C., Rebar, R. W., Legro, R. S., Balen, A. H., Lobo, R., Carmina, E., Chang, J., Yildiz, B. O., Laven, J. S. E., et al. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.09.024 · Cited by 1,976 · cited 2×
“Guidelines do not recommend one formulation over another, due to the lack of a clear evidence for differences in effectiveness and risk among the various progestins when used in combination with low-dose estrogen [6,22,23].”
BackgroundDiamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947 · cited 2×
“PCOS associated IR selectively affects metabolic but not mitogenic or steroidogenic insulin actions [26,27].”
BackgroundLegro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919 · cited 3×
“Based on the available limited data, use of statins is not routinely recommended in women with PCOS unless they meet current indications for statin therapy [23].”
BackgroundRosenfield, R. L., & Ehrmann, D. A. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1104 · Cited by 1,603 · cited 3×
“PCOS associated IR selectively affects metabolic but not mitogenic or steroidogenic insulin actions [26,27].”
BackgroundCriteria, Prevalence, and Phenotypes of Polycystic Ovary Syndrome
Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavrilova-Jordan, L., & Azziz, R. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.05.003 · Cited by 1,358 · cited 1×
“Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disorder in reproductive age women with a worldwide prevalence ranging from 4 to 21% [1,2].”
BackgroundRosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Research works printed but not linked: 4
- Lopez LM, 2019, Cochrane Database Syst Rev, 2014, CD006133
- Fraison E, 2020, Cochrane Database Syst Rev, 8, CD005552
- Miao C, 2020, Exp Ther Med, 19, 2641
- Coutinho EA, 2019, Med Sci (Basel), 7, 84
Cited by
Polycystic Ovary Syndrome: Pathophysiology and Therapeutic Opportunities
Dong, J., & Rees, D. A. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2023-000548 · Cited by 123
“131 Nevertheless, in a network meta-analysis of 941 women with polycystic ovary syndrome and overweight or obesity, liraglutide was superior to metformin (mean difference −3.82, 95% confidence interval −4.44 to −3.20) and orlistat (−1.95, −3.74 to −0.16) in reducing body weight.”
InfluentialYun, C., Yan, S., Liao, B., Ding, Y., Qi, X., Zhao, M., Wang, K., Zhuo, Y., Nie, Q., Ye, C., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01041-8 · Cited by 110
“In general, the therapeutic effect of GLP-1R agonists on PCOS is believed to be due to the improvement of insulin resistance 47,48 .”
Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?
Pugliese, G., de Alteriis, G., Muscogiuri, G., Barrea, L., Verde, L., Zumbolo, F., Colao, A., & Savastano, S. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02084-6 · Cited by 29
Fereidouni, F., Kashani, L., Amidi, F., Khodarahmian, M., Zhaeentan, S., Ardehjani, N. A., & Rastegar, T. (2024) · Inflammopharmacology · doi:10.1007/s10787-024-01504-0 · Cited by 22
“Currently, there is no one ideal treatment for all women with PCOS, so physicians must treat them symptomatically (Helvaci and Yildiz 2023; Sadeghi et al. 2022).”
Naeem, I., Zehra, A., Rehman, F., Hussain, A., Hussain, N., Hussain, N., WASEEM, M., Alqahtani, R. M., Shamlan, G. H., Ahmed, I. A. M., et al. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01741-z · Cited by 22
“Similarly, recombinant FSH is increasingly used for follicular development, whereas letrozole is preferred for regulating irregular periods, ovulation, and fertility [132].”
Metadata
- Authors
- Helvaci, N., & Yildiz, B. O.
- Affiliations
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Hitit University School of Medicine, Corum, Turkey
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2022-08-07
- Volume
- 24
- Issue
- 1
- Pages
- 105-120
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W4288884761
- Cited by
- 35
- References
- 104
- Citations by year
- 2026: 12 · 2025: 6 · 2024: 10 · 2023: 7
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Keywords
- polycystic ovary syndrome, pharmacotherapy, metabolic abnormalities, endocrine disorders, reproductive abnormalities, personalized treatment, multi-target therapy, PCOS pathogenesis
- MeSH terms
- Female, Humans, Phenotype, Polycystic Ovary Syndrome, Pregnancy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current and emerging drug treatment strategies for polycystic ovary syndrome. https://app.cochat.ai/papers/10.1080/14656566.2022.2108702
- The paper
- Helvaci, N., & Yildiz, B. O. (2023). Current and emerging drug treatment strategies for polycystic ovary syndrome. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2022.2108702
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.